Evaxion Announces Business Update and First Quarter 2024 Financial Results
COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio...
News
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients...
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Single healthcare-focused institutional investor $5 million upfront with up to an additional $10 million of gross proceeds upon the exercise in full...
Longeveron® to Attend BIO International Convention 2024
MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular...
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet...
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company...
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects...
Spectral AI to Participate in Benzinga’s “AI Unleashed: Exploring the Possibilities” Virtual Event
DALLAS, May 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence...
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio’s Lead Compound PH-762
Intratumoral PH-762 has encouraging safety profile in the initial cohortEscalation to proceed to next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - May...
Q1 Interim Report January-March 2024
STOCKHOLM, SWEDEN / ACCESSWIRE / May 28, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) Press release: Stockholm, 28 May 2024. PMD...
Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington’s Disease
Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington's diseaseOne of Evotec's largest strategic drug...
IRLAB Presents at Redeye Growth Day 30 May
GOTHENBURG, SE / ACCESSWIRE / May 28, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 28, 2024 - IRLAB Therapeutics...
Cloud DX Will Report First Quarter 2024 Results on May 30, 2024. Company will also extend the closing date of previously announced Private Placement
KITCHENER, ON / ACCESSWIRE / May 27, 2024 / Cloud DX (TSXV:CDX)(OTCQB:CDXFF), will post its Q1-2024 financial results after market...
PMD Device Solutions AB (Publ) Postpones the Annual General Meeting
STOCKHOLM, SWEDEN / ACCESSWIRE / May 27, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) PMD Device Solutions AB (publ) cancels the...
James Anderson and Life Beyond Barriers, LLC Provide Update on Holdings of MyndTec Inc.
Detroit, Michigan--(Newsfile Corp. - May 27, 2024) - James Anderson and Life Beyond Barriers, LLC (together, the "Investor") filed an...
MyndTec Inc. Completes Fifth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - May 27, 2024) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), an emerging player in...
Red Light Holland Completes First Phase of Natural Psilocybin Extraction with PharmAla, Initiates Optimization Process
Toronto, Ontario--(Newsfile Corp. - May 27, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light...
IRLAB Appoints Kristina Torfgård as New CEO
GOTHENBURG, SE / ACCESSWIRE / May 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 27, 2024 - IRLAB Therapeutics...
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract;Rapid and sustained improvements in hematuria over 36...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine)...